Myelodysplastic syndrome/acute myelogenous leukaemia related to adjuvant chemotherapy with oral pyrimidine anti-metabolites

被引：6

作者：

Abe, M ^{[1
]}

Tanaka, Y ^{[1
]}

Shinohara, M ^{[1
]}

Kosaka, M ^{[1
]}

Matsumoto, T ^{[1
]}

机构：

[1] Univ Tokushima, Sch Med, Dept Internal Med 1, Tokushima 770, Japan

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2000年 / 111卷 / 02期

关键词：

therapy-related MDS/AML; pyrimidine anti-metabolites; tegafur; uracil;

D O I：

10.1046/j.1365-2141.2000.02357-2.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：712 / 713

页数：2

共 4 条

[1] ESTIMATING MAXIMUM LIMITS TO MUTAGENIC POTENCY FROM CYTOTOXIC POTENCY [J].

CARVER, JH ;

HATCH, FT ;

BRANSCOMB, EW .

NATURE, 1979, 279 (5709) :154-156

[2] URACIL ENHANCEMENT OF 5-FLUORODEOXYURIDINE INCORPORATION INTO HUMAN-BREAST CARCINOMA DEOXYRIBONUCLEIC-ACID [J].

KUFE, DW ;

HERRICK, D ;

GUNNER, L .

BIOCHEMICAL PHARMACOLOGY, 1984, 33 (14) :2329-2331

[3]

Park DJ, 1996, SEMIN HEMATOL, V33, P256

[4] Adjuvant chemotherapy after complete resection in non-small-cell lung cancer [J].

Wada, H ;

Hitomi, S ;

Teramatsu, T ;

Ikeda, S ;

Okada, Y ;

Kusakawa, M ;

Soejima, R ;

Teramoto, S ;

Tomita, M ;

Hirakawa, A ;

Maeda, M ;

Yamamoto, K ;

Monden, Y ;

Kimura, I ;

Ohta, M ;

Ayabe, H ;

Ito, M ;

Kato, H ;

Genka, K ;

Shimizu, N ;

Tsubota, N ;

Nakamoto, K ;

Namikawa, S ;

Matsubara, Y ;

Okimoto, J .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1048-1054

← 1 →